Atea Pharmaceuticals (AVIR) Financials

Atea Pharmaceuticals (NASDAQ: AVIR) remains a cash-rich, pre-revenue biotech, but the latest quarter shows continued heavy operating losses and a steady drawdown of its balance-sheet cushion.

For Q1 2026, the company reported no revenue and a net loss of $45.4 million, roughly in line with the prior quarter and slightly worse than the $44.9 million loss in Q4 2025. Operating expenses were the main driver, with R&D spending of $41.1 million and SG&A of $6.9 million. Atea offset part of that loss with $2.6 million of interest and investment income, but it was not enough to move the company close to breakeven.

Cash flow also remained negative. Atea used $46.4 million in operating cash during the quarter, compared with $28.2 million in Q4 2025 and $32.9 million in Q2 2025. Investing activity was positive this quarter because the company sold more investments than it purchased, generating $29.7 million in net investing cash. Even so, total cash and equivalents fell by $16.4 million in Q1 2026.

The balance sheet still looks strong in absolute terms, with $79.3 million in cash and $176.7 million in short-term investments, or about $256 million of liquid assets. That said, this is down from roughly $339 million of liquid assets at the end of Q3 2025 and $385 million at Q2 2025. Shareholders’ equity also declined to $233.7 million from $315.8 million at Q3 2025, reflecting ongoing losses.

Over the past year, the trend has been mixed:

• Atea still has a substantial cash and investment position, which gives it runway to keep funding development.
• Interest and investment income remains meaningful, helping partially offset operating losses.
• The company continues to report no revenue, so the investment case still depends on pipeline progress rather than commercial execution.
• Liquidity is healthy today, but the balance sheet has been shrinking quarter by quarter as losses accumulate.
• Operating losses remain large, with quarterly net losses consistently in the $34 million to $63 million range over the last four quarters.
• R&D spending remains high, which is typical for a biotech company but also means ongoing cash burn.
• The company’s liquid assets have declined materially from more than $430 million at Q1 2025 to about $256 million at Q1 2026.
• Shares outstanding remain elevated, which can dilute future per-share value if additional capital is needed.

Bottom line: Atea is still funded for the near term, but the financial statements show a company that is burning cash without revenue. For investors, the stock will likely remain highly dependent on clinical and pipeline milestones rather than current financial performance.